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http://dx.doi.org/10.1016/j.ccr.2012.12.001SUMMARYUsing sequential gene expression profiling (GEP) samples, we defined a major functional group related to
drug resistance that contains chromosomal instability (CIN) genes. One CIN gene in particular, NEK2, was
highly correlated with drug resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing
NEK2 in cancer cells resulted in enhancedCIN, cell proliferation and drug resistance, while targetingNEK2 by
NEK2 shRNA overcame cancer cell drug resistance and induced apoptosis in vitro and in a xenograft
myeloma mouse model. High expression of NEK2 induced drug resistance mainly through activation of
the efflux pumps. Thus,NEK2 represents a strong predictor for drug resistance and poor prognosis in cancer
and could be an important target for cancer therapy.INTRODUCTION
Multiple myeloma (MM) is the second most common hemato-
logic malignancy, and affects over 20,000 patients each year in
the United States, with nearly 11,000 deaths during the same
time period (Jemal et al., 2009). A major reason for cancer treat-
ment failure is the existence of a drug-resistant subclone, either
present at diagnosis or developed during treatment. To achieve
a cure for myeloma, a better understanding of the genetic
makeup of these drug-resistant myeloma cells is required so
that these cells can be specifically targeted.
Traditional prognostic factors such as b2-microglobulin,
albumin, and C-reactive protein account for at most 15%–
20% of the heterogeneity in outcomes. Currently, the best
marker for incurable myeloma is the presence of abnormalSignificance
Drug resistance is a universal problem with current cancer the
especially NEK2, and drug resistance are closely correlated a
Furthermore, targeting NEK2 can overcome drug resistance an
have the potential to translate into very important prognostic
been shown to be associated with aggressive cancer behavio
our findings should also apply to other hematologic malignanc
48 Cancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc.metaphase cytogenetics, but even its prognostic value is
limited because its presence accounts for less than 30% of
the observed variability in outcome of newly diagnosed patients
(Calasanz et al., 1997). Using molecular genetic tools, such as
FISH analysis, many of the partners involved in translocations
with 14q32 (heavy chain gene locus) in myeloma have been
identified (Avet-Loiseau et al., 2002). These include t(4;14)
involving FGFR3/MMSET, t(14;16) involving c-MAF, and
t(14;20) involving MAF-B. These translocations are correlated
with poor prognosis and are very often associated with chro-
mosome 13 deletion on metaphase cytogenetics (Moreau
et al., 2002). Large sample FISH studies also identified that
17p13 (p53 gene locus) deletion was a poor prognostic indi-
cator (Xiong et al., 2008). Furthermore, global gene expression
profiling (GEP) has emerged as a powerful tool to classifyrapies. We demonstrate that overexpression of CIN genes,
nd lead to a poor outcome in myeloma and other cancers.
d inhibit cancer cell growth in vitro and in vivo. Our findings
and therapeutic clinical tools. Overexpression of NEK2 has
r and poor prognosis in many malignancies and, therefore,
ies and solid tumors.
Cancer Cell
Role of NEK2 in Cancer Drug Resistancedisease subtypes, to develop robust prognostic models, and to
identify new drug resistance-associated targets in cancers
(Shipp et al., 2002). Based on GEP, we and others have identi-
fied a 70 high-risk gene model and molecular and genetic
myeloma subgroups that are linked to patient outcome (Berg-
sagel et al., 2005; Shaughnessy et al., 2007). Because GEP
data can be obtained repeatedly over time, we hypothesize
that it is possible to monitor, during therapy, genetic changes
associated with the emergence of a drug-resistant cancer cell
population. We therefore performed sequential GEPs to define
a myeloma transcriptome either after chemotherapy or at
relapse occurring early after treatment (early relapse) indicative
of a drug-resistant tumor subpopulation.
Our goal in this study is to identify a reliable, clinically useful
prognostic gene expression signature that offers clinical oppor-
tunities for predicting drug resistance and developing treatments
in myeloma and other cancers. We also determine the effects of
NEK2 overexpression on disease progression and drug resis-
tance and explore how high expression of NEK2 induces drug
resistance in cancer cells.
RESULTS
Sequential Analyses of Gene Expression Profiling
Reveal a Chromosomal Instability Signature Associated
with Myeloma Drug Resistance and Early Disease
Relapse
We compared GEP of 19 paired myeloma cell samples
collected at diagnosis and again after induction chemotherapy
(before first stem cell transplant). A total of 615 probe sets dis-
played significant differential expression. Similarly, we
compared the GEP of 51 paired myeloma samples collected
at baseline and at early relapse and found 864 differentially ex-
pressed genes. By intersection analyses of these two compar-
isons, we identified 56 common genes with significantly upre-
gulated expression both after chemotherapy and at relapse
(Figures 1A and 1B; Table S1 available online). The major
functional group including ten genes (TOP2A, CDC20,
TRIP13, NEK2, AURKA, RRM2, CCNB1, KIF4A, CEP55, and
PBK), with a significant negative impact on survival (hazard
ratio [HR] R 2), belongs to the well-established chromosomal
instability (CIN) signature (Carter et al., 2006). Importantly,
serial GEPs obtained pre-first, pre-second, and post-second
autologous stem cell transplants (ASCT) showed either
a continuing increase of CIN signature or a stable high level
of CIN signature (Figure 1C). Supervised clustering using these
ten CIN genes was applied to plasma cells from 22 healthy
donors, 44 patients with monoclonal gammopathy of undeter-
mined significance (MGUS), 351 patients with newly diagnosed
MM, and nine human myeloma cell lines. Results revealed
that a small population of patients with newly diagnosed
MM (10%) showed a pattern with very high expression levels
of this CIN signature, similar to that of MM cell lines (which
are derived from terminal MM patients) (Figure 1D). The
mean expression levels of CIN genes defined a high-risk
score associated with significantly shorter duration of
response, of event-free survival (EFS) (Figure 1E, p < 0.001;
HR = 4.6), and of overall survival (OS) (Figure 1F: p < 0.001;
HR = 5.2).NEK2, a CIN Gene, Is Linked to Poor Survival in MM
and Other Cancers
Since drug resistance is associated with poor prognosis, we also
correlated the gene expression of the 56 genes associated with
drug resistance with clinical outcomes. A Kaplan-Meier survival
analysis was performed on the Total Therapy 2 (TT2) cohort,
which included 668 patients with newly diagnosed myeloma,
and available GEP on the last 351 patients enrolled (Barlogie
et al., 2006). The correlation between gene expression and
survival was determined by the p value and HR at the best
expression signal cut-off using R-package. NEK2 was the
gene most strongly associated with inferior survival in unad-
justed log rank tests (Table S1).
As shown in Figure 2, the top 13% of MM patients with the
highest NEK2 expression had a significantly inferior EFS, OS
(Figures 2A and 2B, both p% 0.0001), and postrelapse survival
in TT2 (Figure 2C, p < 0.0001), as well as in the successor study
TT3 (Figures 2D and 2E, p < 0.0001 and p = 0.0015, respectively).
On correlation analyses of clinical characteristics, NEK2 gene
expression represented an independent factor associated with
poor prognosis in TT2 (Table 1). Patients with highNEK2 expres-
sion level had high levels of creatinine (p = 0.012) and lactate
dehydrogenase (LDH) (p = 0.004), and low levels of albumin
(p = 0.018); an increased frequency of hypodiploidy defined by
metaphase cytogenetic analysis (p < 0.001), of deletion of chro-
mosome 13 by metaphase analysis (p = 0.001), of amplification
of 1q21 by FISH analysis (p < 0.001); and increased numbers
of focal myeloma bone lesions on magnetic resonance imaging
(p = 0.010). Similarly, the high-risk group defined by the 70-
gene model, and the clinically more aggressive subgroups of
the MMSET/FGFR3, MAF/MAFB, and Proliferation (PR) predo-
minated in the high NEK2 cohort (p < 0.001). On multivariate
cox regression analysis, high NEK2 expression independently
conferred inferior OS (Table 1, p = 0.032).
To examine the clinical implication of high NEK2 expression in
other cancers, we used microarray data sets and associated
clinical information of seven different cancers, including acute
myeloid leukemia (Figure S1A), bladder cancer (Figure S1B),
breast cancer (Figure S1C), glioma (Figure S1D), lung adenocar-
cinoma (Figure S1E), mantle cell lymphoma (Figure S1F), and
mesothelioma (Figure S1G). We found that overexpression of
NEK2 conferred an inferior survival in all seven cancers (Figures
S1A–S1G, p < 0.0001). NEK2 expression was also significantly
upregulated compared to normal cells in all of the examined
cancers, including head and neck squamous cell carcinoma
(Figure S1H), bladder carcinoma (Figure S1I), glioblastoma
(Figure S1J), T cell acute lymphoblastic leukemia (Figure S1K),
colon carcinoma (Figure S1L), hepatocellular carcinoma (Fig-
ure S1M), melanoma (Figure S1N), and ovarian adenocarcinoma
(Figure S1O).
Increased NEK2 Expression Induces Drug Resistance,
Cell Proliferation, and Chromosomal Instability in
Cancer
To test the functional role of NEK2, we overexpressed NEK2 by
lentivirus-mediated NEK2-cDNA transfection in normal fibro-
blasts BJ; the MM cell lines ARP1, KMS28PE, and OCI-MY5;
the lung cancer cell line H1299; and the breast cancer cell
line MCF7 (Figure 3A). NEK2 overexpression significantlyCancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc. 49
Figure 1. Identification of Genes Related to Myeloma Drug Resistance and Disease Relapse
(A and B) Heat maps of the 56 differentially expressed genes in paired myeloma samples at baseline and either after chemotherapy (n = 19) (A) or
at relapse (n = 51) (B). Patient samples were plotted on the vertical axis and the gene probe sets were listed on top along the horizontal axis. See also
Table S1.
(C) A complete sample set (at diagnosis, pre-first, pre-second, and post-second transplants) was available for nine of the 19 patients. The expression of CIN
genes increased significantly in myeloma cells during chemotherapy, suggesting a strong relationship with drug resistance. Red color for a gene indicates
expression above the median and blue color indicates expression below the median.
(legend continued on next page)
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Role of NEK2 in Cancer Drug Resistanceincreased cell proliferation in both normal and cancer cells
compared with empty vector (EV)-transfected cells (Figures 3B
and 3C).
To examine the effect of NEK2 on cancer cell growth and drug
resistance, a clonogenic soft agar assay was performed using
NEK2 overexpressing MM cell line ARP1 and lung cancer cell
line H1299 treated with different doses of anticancer drugs: bor-
tezomib, doxorubicin, or etoposide. Similar results for these two
cell lines were obtained. Results from the representative ARP1
group are shown in Figure 3D. Cancer cells overexpressing
NEK2 showed a significant increase in colony formation indi-
cating that high levels of NEK2 promote cancer cell proliferation
(Figure 3D, p < 0.05). Furthermore, compared with nontreated
controls, cancer cells overexpressing NEK2 showed only a slight
decrease in their capacity to form colonies for all three drugs
tested at a low dose (Figure 3D). However, control cells trans-
fectedwith EV showed a significant decrease in colony formation
when incubated with these drugs at the same concentrations. To
answer whether NEK2 conferred drug resistance is associated
with decreased apoptosis, the standard apoptosis assay was
performed on the same two cell lines after treatment with the
same drugs for 48 hr. Apoptotic cells were stained by the
APC-conjugated Annexin-V and determined by flow cytometry.
As shown in Figure 3E, overexpression of NEK2 decreases cell
apoptosis after addition of anticancer drugs compared with
controls.
To determine the correlation between NEK2 expression and
cell proliferation, we performed Ki67 immunostaining on 32
primary myeloma cases. Double staining for CD138 and Ki67
was used to identify the myeloma cells. Overall, we observed
a low proliferation index in myeloma cells (Figures 3F and 3H).
NEK2 immunostaining was performed on 26 newly diagnosed
cases. Cells were scored positive for NEK2 if they showed
nuclear expression (Figures 3G and 3I). No significant correlation
was noted between Ki67 and NEK2 expression (p > 0.05). We
further correlated the gene proliferation index (GPI) (Hose
et al., 2011) with NEK2 expression in the 351 TT2 patients with
newly diagnosed myeloma. A high correlation was found
between the GPI50 and NEK2 signal (data not shown; r = 0.83,
p < 0.001). We also found that the predictive value for patient
outcome of NEK2 alone was as high as of that of the GPI 50
genes (Figure S2). To determine whether the increased NEK2
signature in post-treatment samples especially post-second
ASCT is due to contamination with other nonmyeloma cells,
we stained bone marrow samples from nine post-second
ASCT patients, who were in complete remission (CR), using
double staining for CD138 and NEK2. Increased NEK2 expres-
sion in CD138 positive plasma cells (>50%) was noted in five
of nine cases. Expression of NEK2 was significantly higher in
myeloma cells when compared to other hematopoietic cells
(Figures 3J and 3K). NEK2 protein was noted in minority of
normal hematopoietic cells but much weaker than in the
myeloma cells.(D) Gene expression clustergram of 10 CIN genes in plasma cells from 22
diagnosed MM, and nine humanMM cell lines (MMCL). Samples within myeloma
left to right.
(E and F) Kaplan-Meier analyses showed that the top 10%of uniformly-treatedMMTo explore if high expression of NEK2 can induce chromo-
somal instability, we subsequently performed comparative
genomic hybridization (CGH)-array using cell lines transfected
with NEK2 versus wild-type (WT) cell lines, and cell lines trans-
fected with EV versus WT cell lines. Exactly the same genera-
tion of ARP1 and H1299 cell lines was transfected with NEK2
and EV and used to compare with the same generation of
parental cells (WT). The log2 ratio for each probe was displayed
on the vertical axis, and the probe’s genomic location on the
horizontal axis (Figures 4A, 4B, 4E, and 4F). We identified gains
and losses of multiple segments in the NEK2 overexpressing
ARP1 and H1299 but not in the cells transfected with EV. We
chose the chromosomes 4q21 and 21q22 as examples in
Figures 4C and 4G and showed DNA losses in these areas for
ARP1 and H1299, respectively. To verify the array-CGH find-
ings, we subsequently performed FISH analysis using probes
of areas deleted by array-CGH on ARP1 cells (probes
4q21.23 in green) and showed four, four, and three copies,
respectively in the WT, EV, and NEK2 cells (Figure 4D). Probe
21q22 (LSI21 in red) showed five, five, and two copies in the
H1299 WT, EV, and NEK2 cells (Figure 4H), respectively.
However, control FISH probes chosen from random segments
of each cell line, which did not show gain or loss by array-
CGH, also did not show a difference in copy number by FISH
analysis.
Knockdown of NEK2 by shRNA Inhibits Myeloma Cell
Growth and Decreases Drug Resistance In Vitro and in
NOD-Rag/null Gamma Mice
To examine the function of NEK2 in promoting cancer cell
survival, four specific shRNAs against NEK2 gene (sh1-4) were
designed. A tetracycline-inducible lentiviral expression system
containing shRNA to NEK2 was used to knockdown NEK2 in
tumor cells; sh1-3 target theNEK2 coding region and sh4 targets
the 30 untranslated region (UTR). Real-time PCR confirmed
a remarkable downregulation of NEK2 expression in ARP1 MM
cells after transfection of these NEK2-shRNAs, especially sh3
(Figure S3A). NEK2-shRNA-induced growth inhibition and cell
death were examined daily. Cells were cultured for 6 days and
nontarget scramble-transfected cells were used as controls.
As shown in Figures S3B and S3C, all four NEK2-shRNAs signif-
icantly induced growth inhibition (Figure S3B) and cell death (Fig-
ure S3C) compared with the scrambled controls. To address the
issue of off-target toxicities, we doubly transfected ARP1 cells
with NEK2-sh4 and the NEK2-cDNA, which contained only the
coding region ofNEK2, and cell growth was examined. As shown
in Figure S3D, forced overexpression of NEK2 in ARP1 cells
successfully abrogated cell growth inhibition induced by sh4,
strongly suggesting that the cytotoxic effects induced by sh4
were directly related to specific knockdown of NEK2. We then
chose the most potent NEK2-sh3 to knockdown NEK2 in other
cancer cell lines, including KMS28PE, OCI-MY5, H1299, and
MCF7 cells. Figures 5A and 5B confirm that NEK2-knockdownhealthy subjects (NPC), 44 subjects with MGUS, 351 patients with newly
risk groups were ordered so that the predicted risk increases continuously from
patients with high CIN signatures had a significantly inferior EFS (E) andOS (F).
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Figure 2. High NEK2 Expression Is Linked
to a Poor Prognosis in Myeloma
(A andB) Kaplan-Meier analyses of EFS (A) andOS
(B) revealed inferior outcomes among the 47
patients with NEK2 high expression compared
with the remaining 304 patients with NEK2 low-
expression in the TT2 trial.
(C) Kaplan-Meier analysis of post-relapse survival
was shown in relation to NEK2 expression deter-
mined by GEP. High expression of NEK2 con-
ferred a short post-relapse survival.
(D and E) Kaplan-Meier analyses of EFS (D) and
OS (E) revealed an inferior outcome among the 25
patients with NEK2 high-expression compared
with the remaining 187 patients with NEK2 low-
expression in our TT3 trial.
See also Figure S1.
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Role of NEK2 in Cancer Drug Resistanceinduced significant cell growth inhibition and apoptosis in all
these cell lines compared with the scrambled controls. Western
blots confirmed efficient knockdown of NEK2 in these cells
(Figure 5C).
To examine the mechanism by which NEK2-knockdown
induced cell death, NEK2-silenced ARP1, KMS28PE, OCI-
MY5, H1299, andMCF7 cells were cultured for 3 days. As shown
in Figure 5C, increased levels of cleaved PARP, and activation
of caspase-3, caspase-8, and caspase-9 were observed by
the appearance of the processed forms on western blots in
NEK2-knockdown cancer cells compared with scrambled cells,52 Cancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc.indicating that both death receptor-
dependent (caspase 8) and -independent
(caspase 9) apoptotic pathways were
involved.
We also tested the effects of condi-
tional knockdown of NEK2 on MM cell
growth in vivo. In this study (5 mice in
each group), ARP1 MM cells were trans-
duced with NEK2-shRNA or scrambled
RNA vectors and then injected subcuta-
neously into the right abdomen of NOD-
Rag/null gamma mice. Ten days after
engraftment of the tumors, viral expres-
sion was induced by the addition of doxy-
cycline to the drinking water. As shown in
Figure 5D, tumor cells in control mice
continued to grow rapidly while activation
of NEK2 shRNA, validated by downregu-
lation of NEK2 onwestern blot (Figure 5F),
resulted in a marked inhibition of tumor
growth and decrease in tumor volume
(Figure 5E).
We subsequently tested if downregu-
lation of NEK2 expression could
decrease drug resistance to bortezomib
using the bortezomib-resistant (DR)
ARP1 cell line. Viral expression was
induced by the addition of doxycycline
to the drinking water 15 days after the
injection of tumor cells (three mice ineach group). Bortezomib was given by intraperitoneal injection
at the time the tumor could be palpated under the skin. The
upper panel of Figure 5G shows similar tumor sizes after
15 days in one representative mouse from each group. We
found that knockdown of NEK2 could inhibit tumor growth
(the bottom panel of Figure 5G, group 3 versus group 1, and Fig-
ure 5H) and that bortezomib could further inhibit tumor growth
only in tumors with downregulated NEK2 (Figures 5G, group 4
versus group 3, and 5H) but not in tumors with high levels of
NEK2 (Figures 5G, group 1 versus group 2, and 5H). Western
blots confirmed that NEK2 expression was indeed
Table 1. The Correlation of NEK2 Expression and Clinical
Characteristics in TT2
Characteristics
High NEK2
(%, n = 47)
Low NEK2
(%, n = 304) p Value
Age at least 65 years 19.6 22.3 NS
Female sex 39.1 43.9 NS
White race 95.7 87.5 NS
IgA isotype 30.4 27.5 NS
CRP at least 4.0 mg/l 11.1 5.3 NS
b2-Microglobulin at least
4.0 mg/l
45.7 32.8 NS
Hemoglobin less than 10 g/dl 34.1 24.0 NS
Bone marrow plasma cells
(by aspiration) 33% or
greater
48.6 53.2 NS
Albumin less than 3.5 g/dl 52.5 34.1 0.018
Creatinine at least 2.0 mg/dl
(221 mmol/l)
22.7 9.8 0.012
MRI focal bone lesions, at
least three
76.1 55.8 0.010
LDH at least 190 IU/l 53.3 31.3 0.004
Chromosomal abnormalities
(by G-banding)
65.2 30.8 <0.001
Hyperdiploid 21.7 18.0 NS
Hypodiploid 43.5 11.1 <0.001
Deletion of chromosome 13 72.1 46.1 0.001
Amplification of 1q21 85.0 37.6 <0.001
High-risk model (70-gene) a 58.7 6.2 <0.001
Subgroups with poor
prognosis (PR/MS/MF)a
82.6 18.4 <0.001
Multivariate Analysis of Clinical Characteristics Affecting OSb
NEK2 high 13% 0.032
High-risk model (70-gene)a 0.001
Subgroups with poor
prognosis (PR/MS/MF)a
0.040
aThe high-risk model (Shaughnessy et al., 2007) and PR/MS/MF
subgroup (Zhan et al., 2006) designation has been described elsewhere.
bPredictors with p > 0.05 for OS outcome: aged 65 years or older, IgA iso-
type, metaphase cytogenetic abnormalities, albumin of 35 g/l or less, b2
microglobulin 4 mg/l or above, LDH 190 IU/l or above, creatinine at least
2 mg/dl (221 mmol/l), bone marrow plasma cells (by aspiration) 33% or
greater, and C-reactive protein of 4 mg/l or more.
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cells (Figure 5I).
Overexpression of NEK2 Activates both AKT and
Canonical Wnt Signaling, Resulting in Increased Cancer
Cell Proliferation, Drug Resistance, and Chromosomal
Instability
NEK2 regulates the mitotic centrosome separation through
reversible phosphorylation of its substrates c-NAP1 (Fry et al.,
1998), protein phosphatase 1 (PP1) (Helps et al., 2000), NIP1/
centrobin (Sonn et al., 2009), b-catenin (Bahmanyar et al.,
2008), and SGO1 (Fu et al., 2007) in yeast. In our study, we per-
formed co-immunoprecipitation (CO-IP) and mass spectrometryin cancer cells to identify NEK2 binding proteins. We found that
NEK2 directly binds to PP1, mitotic arrest deficient 2 (MAD2), cell
division cycle protein 20 (CDC20), b-catenin, highly expressed
protein in cancer (HEC1), and protein regulator cytokinesis 1
(PRC1) (data not shown). We were particularly interested in
PP1, b-catenin, CDC20, and MAD2, because they are involved
not only in chromosomal instability, but also in cancer cell drug
resistance and proliferation (Figure S4A). Western blots were
applied to further elucidate the activation of the key signaling
pathways related to drug resistance and anti-apoptosis,
including PP1 and b-catenin. As shown in Figure 6A, overexpres-
sion of NEK2 not only phosphorylated PP1 at Thr-320 resulting in
inhibition of PP1 activity (Kwon et al., 1997), but also activated
canonical Wnt signaling evidenced by nuclear accumulation of
b-catenin. We also examined two main mechanisms related to
drug resistance, the efflux pumps and the mitotic checkpoint
proteins, to see if increased expression of these proteins is
associated with overexpression of NEK2 or its targets. Our
studies showed that overexpression of NEK2 upregulated
mitotic checkpoint protein MAD2 and ABC transporter family
members, including ABCB1 (p-glycoprotein, MDR1), the multi-
drug resistance protein ABCC1 (MRP1), and the breast cancer
resistant protein ABCG2 (BCRP) (Figure 6A). Consistently,
downregulation of NEK2 by shRNA decreased the expression
of phosplorylated PP1, AKT, nuclear b-catenin, and ABC
transporters (Figure 6B). High expression of NEK2 promoted
a higher efflux of the hydrophilic eFluxx-ID gold fluorescent
dye from cancer cells compared with control cells (Figure 6C).
Verapamil, an ABC transporter inhibitor, was able to abrogate
part of the NEK2-induced drug resistance by showing a de-
crease in colony formation (Figure 6D). These results strongly
suggest that PP1, Wnt, mitotic checkpoint proteins, and ABC
transporter family signaling pathways are the downstream
targets of NEK2.
It has indeed been confirmed that PP1 regulates the AKT
signaling transduction pathway to control cell survival and differ-
entiation (Xiao et al., 2010), and that this pathway plays a central
role in cell proliferation and drug resistance. We observed a
high correlation between deactivation of PP1 (increase of phos-
phorylated PP1 at Thr-320) and the activation of AKT pathways
(Figure 6A). We thus determined the functional role of AKT
pathway in NEK2 inducing cell proliferation and drug resistance.
A specific AKT inhibitor, LY294002, at the dose of 10 mM for 12 hr
was used to treat NEK2-transfected ARP1 cells. LY294002 treat-
ment decreased p-AKT in both EV - and NEK2-transfected
myeloma cells compared with untreated controls on western
blot (Figure 6E), confirming its specificity. LY294002 inhibited
the ABC transporters ABCB1, ABCC1, and ABCG2 in ARP1
NEK2-OE cells (Figure 6E). LY294002 inhibited to efflux of hydro-
philic eFluxx-ID gold fluorescent dye in ARP1 NEK2-OE cells
further supporting that AKT regulates the activity of ABC family
(Figure 6F) and decreased colony formation in ARP1 NEK2-OE
cells (Figure 6G).
Activation of Wnt signaling induces cancer cell survival and
drug resistance (Gehrke et al., 2009). We have shown that
NEK2 stabilized nuclear b-catenin (Figure 6A). We have further
demonstrated the functional role of canonical Wnt signaling in
NEK2 induced cancer cell proliferation and drug resistance.
Similar to the effect induced by the AKT inhibitor, knockdownCancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc. 53
Figure 3. Overexpression of NEK2 Promotes Cancer Cell Proliferation and Drug Resistance
(A) Western blots showed increased NEK2 expression in the cancer cell lines ARP1, KMS28PE, OCI-MY5, H1299, and MCF7, and normal fibroblasts BJ after
transfection with NEK2-cDNA. EV-transfected cells served as controls.
(legend continued on next page)
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resistance induced by NEK2 (Figure 6G). Interestingly, the AKT
inhibitor LY294002 decreased the nuclear accumulation of
b-catenin in ARP1 NEK2-OE cells, suggesting that activation of
Wnt signaling induced by NEK2 partially depends on AKT
pathway partially (Figure 6E).
In addition, we found that overexpression of NEK2 suppressed
the expression of the pro-apoptotic genes BAD and PUMA
and upregulated the expression of pro-survival genes BCL-
xL and MCL-1, indicating a possible role of NEK2 in anti-
apoptosis (Figure S4B). Finally, the NEK2 cell signaling related
genes were analyzed by using GEP. It is noteworthy that the
76 probe sets related to either overexpressing or silencing
NEK2 have a defined function in DNA replication, cell cycle
progression, chromosome condensation, mitosis, and cytoki-
nesis (TMPO, MYBL1, HMGB1, HPSE, CDC2, KLF14, DUSP4,
MPHOSPH9, PRKDC, CENPF, KLF11, CDCA2, and KIFC1)
(Figures S4C–S4F; Table S2).
DISCUSSION
Ron Morris first described NIMA in 1975 (Morris, 1975). The
NIMA-related family members of serine/threonine kinases
(Neks) are widespread among eukaryotes and are defined by
similarities in their N-terminal catalytic domains to the founding
NIMA member (Oakley and Morris, 1983). Together with the
Polo and Aurora kinase families, the NIMA-related protein
kinases (Nrks or Neks) have been called the third family of mitotic
kinases (Wu et al., 1998). NEK2, a member of the NIMA-related
family, has several putative roles in cell division, most notably
in spindle formation and chromosome segregation (Faragher
and Fry, 2003). Overexpression of active NEK2 leads to CIN
and an aneuploid karyotype (Hayward and Fry, 2006), which
are commonly observed in cancers including virtually all
myelomas. Recently, it has been proposed that an increased
number of chromosome sets can promote cell transformation
and give rise to an aneuploid tumor (Storchova and Kuffer,
2008). In our study, we have demonstrated that overexpression
of NEK2 induced chromosomal instability in cancer evidenced
by multiple segment gains and losses of chromosome. Our
results also demonstrated that the transcriptional level of NEK2
is increased in many aggressive types of cancer. Using the(B and C) Overexpression of NEK2 into cancer cell lines and normal cells increas
means ± SD of three independent experiments.
(D) The cancer cells were fed with medium with or without bortezomib, doxorub
decreased significantly colony efficiency values (shown on the figure) in the contro
was done in triplicate and the representative images of colonies of ARP1-EV and A
the same time for Figure 6G, so the controls used in this Figure and Figure 6G a
(E) ARP1 EV cells showed the sensitivity to all the anticancer drugs using the sta
apoptosis. More apoptotic cells were seen, associated with a greater shift to the r
overexpression showed only a weak right-shifted peak even with high dose trea
(F–I) F and H show double stains for CD138 antibody noted as a brown membr
immunohistochemical staining. G and I demonstrate stains for NEK2 with brow
plasma cells with approximately 5% of CD138 positive plasma cells showing red
Neoplastic CD138 positive plasma cells showed 20%–30% positive nuclear stain
numerous cells in Figure 3I showed positive nuclear Ki67 staining, but lacked CD
(J and K) showed double stains for CD138 noted as a red membrane pattern as
samples. Scale bars, 50 mm.
See also Figure S2.publicly available data sets, we analyzed NEK2 expression
data from a large set of different primary and metastatic tumors
with their normal counterparts serving as controls. In all cancers,
we showed that regardless of the tissue of origin, tumor cells
have significantly increased NEK2 expression. Gene expres-
sion-based survival prediction in multiple independent cancers
showed that overexpression of NEK2 is associated with a poor
clinical outcome. All these findings support the important role
of the NEK2 gene in disease progression not only in MM, but
also in multiple other tumors. When we performed a multivariate
analysis (MVA) with four parameters including the high-risk
model (70 genes), high-risk genetics (MF, MS, PR), GPI50, and
NEK2, only the high-risk 70-gene model and the high-risk
genetics, but not GPI50 and NEK2, were significantly indepen-
dent parameters in the prediction of MM prognosis (data not
shown). This may be because NEK2 is one of the GPI50 genes
and its expression is highly correlated with the high-risk scores
of both the 70-gene model and high-risk genetics. However, as
shown in Table 1, high expression of NEK2 is an independent
prognostic factor in a MVA without GPI50 parameter.
Drug resistance is the most important problem in cancer treat-
ment. Relapse phenotypes may be acquired via therapy-
induced selection of resistant minor clones present at diagnosis
or by direct adaptation to therapy of the original clone. Applying
GEP, our study focused on identifying the genetic make-up of
drug-resistant myeloma cells, which is very different from that
of myeloma cells at diagnosis, when most myeloma cells are
drug-sensitive. In this study, we defined 56 genes associated
with drug-resistant myeloma cells, which either survive intensive
treatments or are present in relapse, occurring early during
treatment. A subset of ten genes, previously related to drug
resistance, belong to the well-established chromosomal insta-
bility signatures. A prominent feature of myeloma is its pro-
nounced genetic instability, which is more reminiscent of solid
tumors than of hematologic malignancies. Cytogenetic and
molecular changes are already present at the premalignant
stages, i.e., MGUS and smoldering myeloma (Kyle and Rajku-
mar, 2006), and increase with conversion to myeloma (Iida and
Ueda, 2003), indicating that genomic instability is an early hall-
mark in myeloma genesis. Aneuploidy and CIN have also been
associated with acquired or intrinsic drug resistance (Kops
et al., 2005).ed cell proliferation in normal and cancer cells. All results were expressed as
icin, and etoposide in plates with single layer agar cultures. Drug treatments
l group, but decreasedmuch less in the NEK2 overexpressing group. The assay
RP1-NEK2 OE were shown (43). Note: we performed all clonogenic assays at
re the same.
ndard apoptotic assay, and the right-shifted peak indicates cells undergoing
ight when higher drug concentrations were applied. The ARP1 cells with NEK2
tment.
ane pattern as well as for Ki67 noted as a red nuclear staining pattern using
n nuclear staining pattern. F and G represented one case showing sheets of
nuclear staining for Ki-67 (F), while NEK2 was positive in half the cells (G). (H)
ing for Ki67, while (I) these cells were completely negative for NEK2. Note that
138 staining, thus reflecting normal hematopoietic cells. Scale bars, 50 mm.
well as for NEK2 noted as a brown nuclear staining pattern in post-2nd ASCT
Cancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc. 55
Figure 4. Overexpression of NEK2 Induces Chromosomal Instability
(A, B, E, and F) Array-CGH showed that genome-wide gains and losses in ARP1 (A and B) and H1299 (E and F) cells transfected with EV versus parental (WT) (A
and E) and NEK2 cDNA (NEK2) versus parental (B and F). Dots represent the log2 ratio of the intensities for each CGH microarray probe plotted versus the
chromosome position. Yellow lines represented the estimated mean of each segment by DNAcopy.
(C) Magnification of a segment of chromosome 4 showed no gain or loss in ARP1 EV versus WT, but losses in ARP1 NEK2 versus WT.
(D) FISH confirmed the loss of 4q21.23 in the NEK2 overexpressing ARP1 cells (three copies) compared to WT ARP1 cells (four copies) and the ARP1-EV (four
copies). The control probe CEP10 (D: orange) showed no difference in any of the three ARP1. Scale bars, 10 mm.
(G) Magnification of a segment of chromosome 21 showed losses in the H1299 transfected with NEK2 cDNA but not in the EV.
(H) FISH confirmed the loss of 21q22 in the NEK2-overexpressing H1299 cells (two copies) compared to the H1299-WT cells (five copies) and the H1299-EV (five
copies). The control probe CEP7 (H, green) showed no difference in all three H1299 lines. Scale bars, 10 mm.
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Figure 5. Silencing NEK2 Expression by shRNAs Induces Cancer Cell Growth Inhibition and Decreases Cell Viability
(A and B) 1.5 3 105 cells from the cancer cell lines ARP1, KMS28PE, OCI-MY5, H1299, and MCF7 were transfected with NEK2-shRNA and cultured for 7 days.
NEK2-shRNA induced significant growth inhibition (A) and decreased cell viability (B). Cells transfected with scrambled (SCR) sequence served as control; results
were expressed as means ± SD of three independent experiments.
(legend continued on next page)
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Cancer Cell
Role of NEK2 in Cancer Drug ResistanceIn this study, we discovered that at least two pathways, PP1/
AKT andWnt signaling, are involved inNEK2-induced cancer cell
drug resistance. It has been revealed that PP1 regulates the AKT
signaling pathway to control cell survival and differentiation (Xiao
et al., 2010). AKT activation is achieved through a series of phos-
phorylation steps, the first and the most important step is the
phosphorylation at Thr-450, followed by the phosphorylation at
Thr-308 and Ser-473 to achieve its full activation (Nicholson
and Anderson, 2002). PP1 is a major phosphatase that directly
dephosphorylates AKT at Thr-450 to modulate its activation.
Our results show that NEK2 binds directly to and phosphorylates
PP1 on Thr-320, which results in the upregulation of phosphory-
lated AKT at Ser-473. ABC transporter family members, ABCB1,
ABCC1, and ABCG2 are known to play a crucial role in the
development of multidrug resistance (Choi, 2005). The ABC
transporters colocalize with and can be activated by direct phos-
phorylation of PIM1 (Xie et al., 2008). Our findings support those
of others that NEK2 stimulates the expression of ABC trans-
porters by activation of AKT and its downstream targets PIM1
and NF-kB, resulting in drug resistance of cancer cells (Misra
et al., 2005; Kuo et al., 2002).
AKT plays a central role in cell proliferation (Brunet et al., 1999).
AKT also suppresses the pro-apoptotic function of BCL2 family
member BAD (Datta et al., 1997) and BAX (Gardai et al., 2004).
AKT functions through Ikk to promote the transactivation
potential and phosphorylation of nuclear factor-kB (NF-kB)
(Dan et al., 2008), which activates transcription of pro-survival
gene members of the BCL2 family (BCL2, BCL-xL, and MCL1)
(Huang, 2000). In this study, we show clearly that NEK2 induces
the expression of pro-survival genes, while inhibiting pro-
apoptotic genes; the AKT inhibitor LY294002 decreases NEK2-
induced colony formation, strongly suggesting that NEK2
induces cell proliferation through AKT signaling.
In the cytoplasm, APC, glycogen synthase kinase-3 (GSK-3)
and AXIN form a b-catenin destruction complex which mediates
the degradation of b-catenin (Bienz, 2002). Activation of AKT by
high expression of NEK2 phosphorylates and deactivates GSK-3
resulting in activation of b-catenin (Monick et al., 2001). Both
MAD2 and BubR1 can bind to CDC20 independently and inhibit
the activation of APC. Loss of APC or GSK-3 function leads to
cytoplasmic b-catenin accumulation and stabilization with
constitutive activation of the canonical Wnt signaling pathway
(Fodde and Tomlinson, 2010). When cytoplasmic b-catenin is
stabilized, it translocates into the nucleus, where it interacts
with a family of T cell factor/lymphocyte enhancer factor
(TCF-LEF) transcription factors to drive cell proliferation by direct
induction of cell cycle regulators, such as c-Myc and cyclin D1(C) Western blots confirmed that NEK2 expression was dramatically decreased in
NEK2 shRNA. Silencing NEK2 induced apoptosis through both death receptor-d
SCR controls.
(D) ARP1 cells were transduced with NEK2 shRNA and SCR control vectors and
mice. Viral expression was induced by the addition of doxycycline to the drinking
shown between the two groups of mice 24 days after injection of ARP1 cells and
(E) Tumor volume assessments showed that mice with NEK2-shRNA had smalle
(F) Western blots showed decreased NEK2 expression in ARP1 cells after NEK2
(G) In the ARP1-DR mice, the groups of 1 to 4 are the group of control (Scr), Scr
(H) Tumor volume assessments showed smaller tumor sizes in NEK2 shRNA-tre
(I) Western blots showed decreased NEK2 expression in ARP1-DR cells after NE
See also Figure S3.
58 Cancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc.(Gehrke et al., 2009). The TCF/b-catenin complex also regulates
ABCB1 by transactivation resulting in drug resistance (Yamada
et al., 2000). Knockdown of b-catenin in the ARP1 cell line
abrogates NEK2- induced colony formation and drug resistance
indicating that b-catenin plays indeed an important role in NEK2
function.
Although we found that mitotic checkpoint protein MAD2 was
upregulated by NEK2, the involvement of this protein on either
PP1/AKT or Wnt signaling or both pathways and the role of the
checkpoint proteins in NEK2 induced cancer cell drug resis-
tance and proliferation still needs to be clarified. However, we
have demonstrated that NEK2 regulates MAD2, which is also
essential spindle checkpoint proteins (Shannon et al., 2002),
MAD2 together with BubR1 transmit a ‘‘wait signal’’ and block
progression into anaphase until all chromosomes have
completely aligned at the metaphase plate (Lee et al., 2004).
MAD2 and CDC20 bind directly to NEK2, and CDC20 overex-
pression is a central feature of the CIN signature (Carter
et al., 2006). We found that NEK2 induces loss of expression
of the tumor suppressor gene APC. Loss of APC function
induces CIN seen in many cancers (Rusan and Peifer, 2008).
In addition, b-catenin binds to NEK2 at the centrosome and is
a key regulator of mitotic centrosome separation (Bahmanyar
et al., 2008).
In summary, both PP1/AKT and Wnt pathways are involved in
NEK2-induced cancer cell drug resistance, proliferation, and
chromosomal instability. Activation of Wnt signaling induced
by NEK2 depends partially on the AKT pathway (Figure 7).
Downregulation of NEK2 by shRNA inhibited myeloma cell
growth and decreased drug resistance in vitro and in NOD-
Rag/null gamma mice. Thus, targeting CIN genes, such as
NEK2, has the potential to eradicate drug-resistant cells when
applied in conjunction with other effective treatments. We are
now exploring how NEK2 regulates its downstream targets
and how interaction among those pathways is regulated by
NEK2.EXPERIMENTAL PROCEDURES
Study Subjects
Nineteen patients with primary MM including 59 samples at baseline, after
chemotherapy (pre-first, pre-second, and post-second ASCTs) were obtained
from Huntsman Cancer Institute, University of Utah according to the protocol
25009. Samples for immunohistochemistry (IHC) staining were obtained from
the University of Utah and ARUP Institute according to the protocol 40253.
Studies are approved by the Institutional Review Board of the University of
Utah. Informed consent was obtained in accordance with the Declaration of
Helsinki.ARP1, KMS28PE, OCI-MY5, H1299, and MCF7 cancer cells transfected with
ependent (caspase 8) and -independent (caspase 9) pathways compared with
then injected subcutaneously into the right abdomen of NOD-Rag/null gamma
water about 10 days after injection of tumor cells. Differences in tumor size are
14 days after the addition of doxycycline.
r tumors than the control group.
shRNA activation (number 3).
+ bortezomib, NEK2-shRNA, and NEK2-shRNA + bortezomib, respectively.
ated mice than in other groups.
K2 shRNA activation (groups 3 and 4).
Figure 6. Overexpression of NEK2Activates both the AKT andCanonicalWnt Signaling PathwaysResulting in Cancer Cell Proliferation, Drug
Resistance and Chromosomal Instability
(A) ARP1 andH1299were transducedwith either NEK2 cDNA or EV using a lentiviral delivery system. Increased expression of phos-PP1 and phos-AKT (Ser-473),
phos-GSK3, phos-NF-kB, MAD2, ABC transporter members (ABCB1, ABCC1, and ABCG2), and nuclear accumulation of b-catenin was observed on western
blotting. We also observed that NEK2 induced decreased expression of APC.
(B) Western blots showed that knockdown NEK2 by shRNA inhibited the activity of AKT and Wnt signaling and decreased the expression of the ABC transporter
members in ARP1 and H1299 cells.
(C) Flow cytometry showed that ARP1 and H1299 cells overexpressing NEK2 have a higher efflux of the hydrophilic eFluxx-ID gold fluorescent dye
indicating a high activity of ABC transporters in these cells. The ABCB1 or ABCC1 inhibitor increased significantly fluorescent dye in ARP1 and H1299
overexpressed NEK2, respectively (p < 0.05). Green tinted and red frame histograms showed fluorescence of pre- and post-inhibitor-treated samples,
respectively.
(legend continued on next page)
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Figure 7. The Model of Our Working Hy-
pothesis
Both PP1/AKT and Wnt pathways are involved in
NEK2 inducing cancer cell drug resistance,
proliferation, and chromosomal instability.
Cancer Cell
Role of NEK2 in Cancer Drug ResistancePlasma cell purifications and GEP and data analysis, using the Affymetrix
U133Plus2.0 microarray, were performed as previously described (Zhan
et al., 2006), and also described in the Supplemental Information.
Array-CGH Data Analysis
Array-CGH data from the Agilent 180,000-feature human CGHmicroarray was
screened for quality using the Agilent-provided quality control metrics. All
arrays passed all ten quality metrics, with signal-to-noise ratios between 72
and 102 (minimum acceptable is 30), and derivative log ratio spread values
between 0.14 and 0.17 (maximum acceptable is 0.30). The data were normal-
ized and segmented in R using both the DNAcopy module (Seshan and
Olshen, 2010) and the snap CGH package (Smith et al., 2009). The resulting
segments were merged with the merge States function (Fridlyand et al.,
2004) which combines adjacent segments with similar log ratios. Segments
containing at least two microarray probes with log2 ratios outside the range
[0.3, +0.3] were considered significant.
NOD-Rag/Null Gamma Mice Model of Human Myeloma
All animal work was performed in accordance with the guidelines of the Insti-
tutional Animal Care and local veterinary office and ethics committee of the
University of Utah, USA (IACUC 08-05004) under approved protocol. ARP1
and ARP1-DR cells were transduced with shRNA and scrambled (SCR) control
vectors. 1.5 3 106 cells (in 100 ml PBS) were injected subcutaneously into the
abdomen of NOD-Rag/null gamma mice. Tumor burdens were monitored by(D) The clonogenic assay showed that the ABC transporter inhibitor verapamil (5 nM) did not inhibit colon
Bortezomib treatment decreased colony efficiency values shown on the figure in the ARP1 EV group, but mu
verapamil and bortezomib showed a significant decrease of colony efficiency value in ARP1 NEK2-OE cells
(E) Western blots showed that the AKT inhibitor LY294002 at a dose of 10 mM for 12 hr (top panel) and b-caten
the ABC transporter members ABCB1, ABCC1 and ABCG2 in both EV and NEK2 OE cells, and LY294002 als
(top panel).
(F) Inhibition of AKT and Wnt signaling decreased the efflux of the hydrophilic eFluxx-ID gold fluorescent dye
ARP1-NEK2 OE cells treated with LY294002 or b-catenin shRNA (p < 0.05). The MAF is shown in the figure.
(G) The clonogenic assay showed that both LY294002 and b-catenin shRNA treatments significantly inhibite
(p < 0.01), especially in the latter (43).
The same membrane was reprobed for the internal control of b-actin or histone H2B for western blot in (A),
60 Cancer Cell 23, 48–62, January 14, 2013 ª2013 Elsevier Inc.tumor volumes. Viral expression was induced by
the addition of doxycycline (2 mg/ml) to the
drinking water (contains 5% sucrose)  10–
15 days after injection of tumor cells.
Soft Agar Clonogenic Assay and Standard
Apoptosis Assay
Ten thousand cancer cells per well were seeded in
12-well plate for layer agar cultures and treated by
multiple drugs at different doses for 3 weeks.
Cells were re-suspended in 0.33% agar in
MyeloCult H5100 cultures /10% FBS. Cells were
fed twice a week by placing two drops of
medium on the layer with or without drugs. All
plates were taken the photos under microscope,
and colony number in the photo was scanned
and counted by the ImageJ. The colony effi-
ciency was calculated as (colony number in the
photo)3 (well area) / (actual area the photo repre-
sent) /10,000 3 100%.
For the standard apoptosis assay, all proce-
dures were followed the standard protocol(Annexin V Apoptosis Detection Kit APC, eBioscience). Cells undergoing
apoptosis were fixed and the fluorochrome-conjugated Annexin-V was used
to visualize the early stage of apoptotic cells and analyzed by flow cytometry.
IHC Staining
Microarray slides were cut at 4 microns on plus slides. Slides are allowed to air
dry. Slides were placed in a 55C–60C oven for 30 min. The IHC stains were
performed on the Ventana automated immunostainer at 37C (XT/ULTRA,
Ventana Medical Systems, Tucson, AZ). Please see details in the Supple-
mental Experimental Procedures.
FISH
FISH was performed on interphase nuclei using standard methods (Xiong
et al., 2008). FISH probes included RP11-397K17 (4q21.23), LSI CEP 10
(control), RUNX1 (21q22), and LSI CEP 7 (control).
Direct Dye Efflux Assay for Multidrug Resistance
The direct dye efflux for multidrug resistance assay was performed essentially
as described in the manufacturer’s instructions (eFluxx-ID Multidrug resis-
tance assay kits, Enzo Life Sciences, USA). 0.35–0.5 3 106 cells were incu-
bated with Gold detection reagent with and without specific inhibitors of
ABCB1, ABCC1, and ABCG2 according to the kit protocol for 30 min in
37C water bath. Cells were suspended in cold PBS for flow cytometry anal-
ysis. The MCF7 cells served as a positive control. The formula of calculationy formation in both EV and NEK2 OE ARP1 cells.
ch less in the NEK2 OE group. The combination of
(43).
in shRNA (bottom panel) inhibited the expression of
o decreased the nuclear accumulation of b-catenin
showing increased significantly fluorescent dye in
d colony formation in both EV and NEK2 OE cells
(B), and (E). See also Figure S4 and Table S2.
Cancer Cell
Role of NEK2 in Cancer Drug Resistanceof multidrug resistance activity factor (MAF) is described in the instruction of
the MDR assay kit.
Statistical Analysis
All data were shown asmeans ± SD. The Student’s t test was used to compare
two experimental groups. In correlation of NEK2 expression with disease
progression, event-free and OSs were measured using the Kaplan-Meier
method, and the log-rank test was used for group comparison. Significance
was set at p < 0.05.
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